Johnson & Johnson's Icotyde Approved by FDA for Psoriasis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy JNJ?
Source: Newsfilter
- FDA Approval: Johnson & Johnson's once-daily oral medication Icotyde has received FDA approval, marking a significant breakthrough as the first oral option for treating moderate to severe plaque psoriasis.
- Significant Market Potential: J&J anticipates peak annual sales of Icotyde exceeding $5 billion, showcasing its strong competitive edge in the treatment market, particularly against injectable drugs like Tremfya and Skyrizi.
- Increased Patient Acceptance: Targeting the IL-23 receptor, Icotyde offers a non-injection treatment option, expected to attract 75% of the 8 million U.S. psoriasis patients who typically avoid injections, significantly enhancing patient treatment experiences.
- Future Expansion Plans: J&J is also testing Icotyde for other autoimmune conditions such as psoriatic arthritis and Crohn's disease, further broadening its market applications and strengthening the company's strategic position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 222.510
Low
190.00
Averages
218.50
High
240.00
Current: 222.510
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Goldman Sachs Retirement Survey Reveals Optimism Gap
- Optimism Gap Phenomenon: The Goldman Sachs Retirement Survey reveals that while 68% of workers are confident about meeting retirement goals, 58% fear outliving their savings, highlighting a structural cost pressure that has reduced the capacity for retirement savings due to rising housing, childcare, and healthcare costs.
- Increased Spending Pressures: Since 2000, housing costs have risen from 21% to 36% of income, childcare from 10% to 25%, and healthcare from 12% to 33%, leading to 67% of respondents feeling overwhelmed by monthly expenses and 64% experiencing financial hardship, which directly impacts their retirement planning.
- Income Strategy Enhancement: The survey indicates that a blended income strategy combining protected lifetime income with investment withdrawals can increase retirement income by 23%, providing stability for essential expenses while addressing long-term growth needs, thereby alleviating financial pressure during retirement.
- Behavioral Factors Impact: Goldman’s research shows that retirees with personalized plans have a savings-to-income ratio of 5.92x compared to 4.68x for those without, underscoring the importance of combining structure and behavior in achieving better retirement outcomes and emphasizing the need for consistent saving and planning.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Investment Opportunities Amid Market Highs
- Market Performance Analysis: The S&P 500 index is trading near all-time highs despite geopolitical conflicts in the Middle East, high oil prices, and concerns about a global recession, indicating market confidence in economic resilience.
- Investment Recommendation: Investors are advised to focus on strong Dividend Kings like Johnson & Johnson and Coca-Cola, both of which demonstrate robust performance in their respective industries and maintain stable cash flows amid economic fluctuations.
- Coca-Cola Performance: Coca-Cola achieved a 3% growth in case volume and a 10% increase in organic sales in Q1 2026, showcasing its strong business resilience despite industry headwinds.
- Johnson & Johnson Outlook: Johnson & Johnson reported a 9.9% sales increase in Q1 2026; despite a slight dip in earnings, management raised the full-year earnings guidance by 7%, aiming for double-digit growth by the decade's end, highlighting its long-term growth potential.
See More
Middle East Conflict Drives Oil Prices Up, Investors Shift to High Dividend Stocks
- Oil Price Impact: The geopolitical conflict in the Middle East has driven oil prices higher, and while the S&P 500 index remains near all-time highs, concerns about a global recession are intensifying, prompting investors to approach potential risks with caution.
- Dividend Stocks Appeal: Investors are strongly advised to shift towards high dividend stocks like Johnson & Johnson and Coca-Cola, both of which are Dividend Kings that have increased dividends annually for over fifty years, demonstrating robust business models and resilience against economic downturns.
- Coca-Cola's Strong Performance: Despite industry headwinds, Coca-Cola achieved a 3% growth in case volume and a 10% increase in organic sales in Q1 2026, indicating strong market performance and a reasonable valuation level.
- Johnson & Johnson Sales Growth: Johnson & Johnson reported a 9.9% sales increase in Q1 2026, and although earnings dipped slightly, management raised its full-year earnings guidance by 7%, reflecting confidence in future growth and an expectation of double-digit growth by the end of the decade.
See More
Trump Denies Plans to Oust FDA Commissioner Makary
- Trump's Denial: Trump stated late Friday that he is unaware of any proposal to oust FDA Commissioner Marty Makary, despite multiple reports suggesting increasing pressure from senior White House officials for his departure, indicating potential internal conflicts.
- FDA Leadership Turmoil: Since Makary's nomination in November 2024, the FDA has seen several high-profile departures, including Richard Pazdur, the director of the Center for Drug Evaluation and Research, and Vinay Prasad, former head of the Center for Biologics Evaluation and Research, highlighting instability within the agency.
- Impact of Media Reports: The Wall Street Journal's initial report on Trump's plans to dismiss Makary contrasts with Trump's claims of ignorance, which may undermine public trust in FDA leadership and the agency's credibility.
- Future Challenges: Given the backdrop of leadership turnover and external pressures, Makary's ability to lead will be increasingly scrutinized, particularly in drug regulation and public health policy, potentially affecting the FDA's decision-making efficiency and public health safety.
See More
Caution Signals Emerge in the Market
- Market Valuation Warning: The Shiller P/E ratio has reached 41, the highest level since the dot-com bubble, indicating that the market may be overvalued and investors should be cautious about potential risks.
- Berkshire's Liquidity Innovation: Berkshire Hathaway holds nearly $397 billion in liquidity, surpassing its $330 billion stock portfolio, indicating a strategy of cash accumulation in anticipation of a discounted market.
- Realty Income Stability: Realty Income boasts a 5.1% dividend yield and a 99% occupancy rate, consistently paying dividends monthly since 1994, demonstrating strong cash flow and market competitiveness.
- Kimberly-Clark's Brand Strength: Kimberly-Clark has increased its dividend for 54 consecutive years, and despite merger cost pressures, its 5.2% dividend yield and stable cash flow suggest it still has the capacity to attract investors.
See More
Goldman Sachs Retirement Survey Reveals Optimism Gap
- Optimism Gap Phenomenon: The Goldman Sachs Retirement Survey reveals that while 68% of workers are confident about meeting retirement goals, 58% fear outliving their savings, highlighting a structural cost pressure that has reduced the capacity for retirement savings due to rising housing, childcare, and healthcare costs.
- Increased Spending Pressures: Since 2000, housing costs have risen from 21% to 36% of income, childcare from 10% to 25%, and healthcare from 12% to 33%, leading to 67% of respondents feeling overwhelmed by monthly expenses and 64% experiencing financial hardship, which directly impacts their retirement planning.
- Income Strategy Enhancement: The survey indicates that a blended income strategy combining protected lifetime income with investment withdrawals can increase retirement income by 23%, providing stability for essential expenses while addressing long-term growth needs, thereby alleviating financial pressure during retirement.
- Behavioral Factors Impact: Goldman’s research shows that retirees with personalized plans have a savings-to-income ratio of 5.92x compared to 4.68x for those without, underscoring the importance of combining structure and behavior in achieving better retirement outcomes and emphasizing the need for consistent saving and planning.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Investment Opportunities Amid Market Highs
- Market Performance Analysis: The S&P 500 index is trading near all-time highs despite geopolitical conflicts in the Middle East, high oil prices, and concerns about a global recession, indicating market confidence in economic resilience.
- Investment Recommendation: Investors are advised to focus on strong Dividend Kings like Johnson & Johnson and Coca-Cola, both of which demonstrate robust performance in their respective industries and maintain stable cash flows amid economic fluctuations.
- Coca-Cola Performance: Coca-Cola achieved a 3% growth in case volume and a 10% increase in organic sales in Q1 2026, showcasing its strong business resilience despite industry headwinds.
- Johnson & Johnson Outlook: Johnson & Johnson reported a 9.9% sales increase in Q1 2026; despite a slight dip in earnings, management raised the full-year earnings guidance by 7%, aiming for double-digit growth by the decade's end, highlighting its long-term growth potential.
See More
Middle East Conflict Drives Oil Prices Up, Investors Shift to High Dividend Stocks
- Oil Price Impact: The geopolitical conflict in the Middle East has driven oil prices higher, and while the S&P 500 index remains near all-time highs, concerns about a global recession are intensifying, prompting investors to approach potential risks with caution.
- Dividend Stocks Appeal: Investors are strongly advised to shift towards high dividend stocks like Johnson & Johnson and Coca-Cola, both of which are Dividend Kings that have increased dividends annually for over fifty years, demonstrating robust business models and resilience against economic downturns.
- Coca-Cola's Strong Performance: Despite industry headwinds, Coca-Cola achieved a 3% growth in case volume and a 10% increase in organic sales in Q1 2026, indicating strong market performance and a reasonable valuation level.
- Johnson & Johnson Sales Growth: Johnson & Johnson reported a 9.9% sales increase in Q1 2026, and although earnings dipped slightly, management raised its full-year earnings guidance by 7%, reflecting confidence in future growth and an expectation of double-digit growth by the end of the decade.
See More
Trump Denies Plans to Oust FDA Commissioner Makary
- Trump's Denial: Trump stated late Friday that he is unaware of any proposal to oust FDA Commissioner Marty Makary, despite multiple reports suggesting increasing pressure from senior White House officials for his departure, indicating potential internal conflicts.
- FDA Leadership Turmoil: Since Makary's nomination in November 2024, the FDA has seen several high-profile departures, including Richard Pazdur, the director of the Center for Drug Evaluation and Research, and Vinay Prasad, former head of the Center for Biologics Evaluation and Research, highlighting instability within the agency.
- Impact of Media Reports: The Wall Street Journal's initial report on Trump's plans to dismiss Makary contrasts with Trump's claims of ignorance, which may undermine public trust in FDA leadership and the agency's credibility.
- Future Challenges: Given the backdrop of leadership turnover and external pressures, Makary's ability to lead will be increasingly scrutinized, particularly in drug regulation and public health policy, potentially affecting the FDA's decision-making efficiency and public health safety.
See More
Caution Signals Emerge in the Market
- Market Valuation Warning: The Shiller P/E ratio has reached 41, the highest level since the dot-com bubble, indicating that the market may be overvalued and investors should be cautious about potential risks.
- Berkshire's Liquidity Innovation: Berkshire Hathaway holds nearly $397 billion in liquidity, surpassing its $330 billion stock portfolio, indicating a strategy of cash accumulation in anticipation of a discounted market.
- Realty Income Stability: Realty Income boasts a 5.1% dividend yield and a 99% occupancy rate, consistently paying dividends monthly since 1994, demonstrating strong cash flow and market competitiveness.
- Kimberly-Clark's Brand Strength: Kimberly-Clark has increased its dividend for 54 consecutive years, and despite merger cost pressures, its 5.2% dividend yield and stable cash flow suggest it still has the capacity to attract investors.
See More
